UnknownNot Applicable

Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

China50 participantsStarted 2019-12-01

Plain-language summary

Severe combined immunodeficiency (SCID) is a rare disease caused by a group of genetic disorders that leads to early death from recurrent infections in affected children.The only curative therapy for SCID is allogeneic hematopoietic stem cell transplantation.Unrelated umbilical cord blood(UCB) is increasingly used as an alternative to bone marrow.

Who can participate

Age range1 Month – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients were diagnosed as severe combined immunodeficiency disease by immunological function and genetic diagnosis center.
✓. Patients have no HLA-matched related donor.
✓. Each organ functions normally and conforms the following inspection criteria:

Exclusion criteria

✕. Patients have any contraindications to hematopoietic stem cell transplantation.
✕. Patients have other serious diseases, such as serious damage to vital organ function: respiratory failure, cardiac insufficiency, decompensated liver dysfunction, renal insufficiency, uncontrollable infection, etc.
✕. The patient is undergoing other drug clinical research.
✕. At the same time suffering from other serious acute or chronic physical or mental illness, or laboratory abnormalities, may affect patient safety and compliance, affecting informed consent, research participation, follow-up or interpretation of results.

What they're measuring

Overall survival rate

Timeframe: 3 years after transplantation

Trial details

NCT IDNCT04172181

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-31

View on ClinicalTrials.gov More Severe Combined Immunodeficiency Disease trials